成纤维细胞生长因子改善脑梗塞的治疗效果
广州暨南大学医药生物技术研究开发中心 (510632)
【摘要】
背景与目的：碱性成纤维细胞生长因子(basic Fibroblast Growth Factor, bFGF)是一种多功能生物活性物质，有促进血管形成，改善微循环，促进中枢及外周神经发育、生长及损伤修复，保护神经细胞凋亡的作用，是维持神经细胞存活的重要营养因子。细胞学和动物实验都证实，bFGF对脑中风可能有较好的保护和治疗作用，本研究探讨bFGF对脑梗塞的临床疗效。
方法：90例脑梗塞患者分为对照组(40例)和治疗组(50例)，两组间的发病时间、年龄、既往史、伴发疾病评分经统计学处理均无显著差异(P>0.05)。对照组使用扩张血管、、控制血压、降低颅内压、降低血粘度及抗感染等常规治疗。治疗组在常规治疗基础上加bFGF(4000 IU/ d)，肌肉注射，连续用药20 d。
, 百拇医药
结果：对照组总有效例数为30例，总有效率75%；治疗组总有效例数为46例，总有效率为92%(P<0.05)。治疗前对照组和治疗组神经功能缺损平均积分分别为22.33±8.31和21.20±8.96，无显著性差异(P>0.05)；治疗后两组积分分别减少到14.38±8.61和11.10±6.02，但治疗组减少幅度大，明显优于对照组(P<0.05)。
结论：采用bFGF治疗能提高常规综合治疗脑梗塞的疗效，降低后遗症的发生率。
Basic fibroblast growth factor can improve the
treatment effect of cerebral infarction
Xiaokun Li, Chengcan Yao
, 百拇医药 Biopharmaceutical Research & Development Center of Jinan University, Guangzhou, China, 510632
Background and objective: Basic Fibroblast Growth Factor, bFGF, is neurotrophic factor with multifunctional bioactivity. It can improve vascular formation and micro-circulation, accelerate the development and growth of central and peripheral nerve system, and protect the apoptosis of nerve cells. In vitro researches showed that bFGF had potential usefulness as a protection and treatment for stroke. In this study, we would evaluate the therapeutic effectiveness of bFGF on cerebral infarction.
, 百拇医药
Methods: 90 patients with cerebral infarction were divided two groups, control group (40 patients) and bFGF treatment group (50 patients). The ages, disease times, case history and concomitant diseases of two group patients had not significantly difference (P>0.05). The control patients were treated with conventional methods, such as expanding the blood vessel, dissolving throbus, controlling the blood pressure, decreasing the intracranial pressure, reducing the blood viscidity and anti-infective etc. The other patients were treated conventional methods, and in addition with bFGF. 4000 IU bFGF was injected intramuscularly every day and continuously treated for 20 days.
, 百拇医药
Results: There were 30 and 46 effective cases in the control group and the bFGf treatment group respectively, and the total effective rate was 75% and 92% of the control group and the bFGf treatment group respectively (P<0.05). The defect index of nerve function of the control group and the bFGf treatment group was 22.33±8.31 and 21.20±8.96 respectively before treatment (P>0.05), and it was decreased to 14.38±8.61 and 11.10±6.02 respectively after treatment (P<0.05).
Conclusion: bFGF can improve the therapeutic effectiveness of cerebral infarction with conventional methods, decrease the disability and incidence rate of sequela, and raise patients’ life quality., http://www.100md.com(李校堃 姚成灿)
【摘要】
背景与目的：碱性成纤维细胞生长因子(basic Fibroblast Growth Factor, bFGF)是一种多功能生物活性物质，有促进血管形成，改善微循环，促进中枢及外周神经发育、生长及损伤修复，保护神经细胞凋亡的作用，是维持神经细胞存活的重要营养因子。细胞学和动物实验都证实，bFGF对脑中风可能有较好的保护和治疗作用，本研究探讨bFGF对脑梗塞的临床疗效。
方法：90例脑梗塞患者分为对照组(40例)和治疗组(50例)，两组间的发病时间、年龄、既往史、伴发疾病评分经统计学处理均无显著差异(P>0.05)。对照组使用扩张血管、、控制血压、降低颅内压、降低血粘度及抗感染等常规治疗。治疗组在常规治疗基础上加bFGF(4000 IU/ d)，肌肉注射，连续用药20 d。
, 百拇医药
结果：对照组总有效例数为30例，总有效率75%；治疗组总有效例数为46例，总有效率为92%(P<0.05)。治疗前对照组和治疗组神经功能缺损平均积分分别为22.33±8.31和21.20±8.96，无显著性差异(P>0.05)；治疗后两组积分分别减少到14.38±8.61和11.10±6.02，但治疗组减少幅度大，明显优于对照组(P<0.05)。
结论：采用bFGF治疗能提高常规综合治疗脑梗塞的疗效，降低后遗症的发生率。
Basic fibroblast growth factor can improve the
treatment effect of cerebral infarction
Xiaokun Li, Chengcan Yao
, 百拇医药 Biopharmaceutical Research & Development Center of Jinan University, Guangzhou, China, 510632
Background and objective: Basic Fibroblast Growth Factor, bFGF, is neurotrophic factor with multifunctional bioactivity. It can improve vascular formation and micro-circulation, accelerate the development and growth of central and peripheral nerve system, and protect the apoptosis of nerve cells. In vitro researches showed that bFGF had potential usefulness as a protection and treatment for stroke. In this study, we would evaluate the therapeutic effectiveness of bFGF on cerebral infarction.
, 百拇医药
Methods: 90 patients with cerebral infarction were divided two groups, control group (40 patients) and bFGF treatment group (50 patients). The ages, disease times, case history and concomitant diseases of two group patients had not significantly difference (P>0.05). The control patients were treated with conventional methods, such as expanding the blood vessel, dissolving throbus, controlling the blood pressure, decreasing the intracranial pressure, reducing the blood viscidity and anti-infective etc. The other patients were treated conventional methods, and in addition with bFGF. 4000 IU bFGF was injected intramuscularly every day and continuously treated for 20 days.
, 百拇医药
Results: There were 30 and 46 effective cases in the control group and the bFGf treatment group respectively, and the total effective rate was 75% and 92% of the control group and the bFGf treatment group respectively (P<0.05). The defect index of nerve function of the control group and the bFGf treatment group was 22.33±8.31 and 21.20±8.96 respectively before treatment (P>0.05), and it was decreased to 14.38±8.61 and 11.10±6.02 respectively after treatment (P<0.05).
Conclusion: bFGF can improve the therapeutic effectiveness of cerebral infarction with conventional methods, decrease the disability and incidence rate of sequela, and raise patients’ life quality., http://www.100md.com(李校堃 姚成灿)